Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Friedrichshafen – page 3

184 clinical trials in Friedrichshafen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Friedrichshafen at a glance
184
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

184 trials in Friedrichshafen

Open in trial search

Breast neoplasm

Recruiting

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Eli Lilly & Co.

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:PF-08049820
  • Sponsor:Pfizer Inc.

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:WSG Women's Cancer Study Group GmbH

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-142
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study of zanidatamab with drug combination for patients with HER2 and PD-L1 positive advanced gastroesophageal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Friedrichshafen

What the registry says about research in the country

01 Dermatology Research

Extensive research focusing on plaque psoriasis and various skin conditions, including innovative therapies for atopic dermatitis and chronic hand eczema. Multiple trials evaluating new treatment approaches for moderate to severe cases.

  • Psoriasis Management
  • Atopic Dermatitis Treatment
  • Hand Eczema Therapy

Studies include assessment of novel topical treatments and oral medications for lasting disease control.

02 Cardiovascular Studies

Critical research examining treatments for atrial fibrillation and stroke prevention, particularly in patients with complex medical histories. Studies focus on innovative anticoagulation strategies and post-procedural care.

  • Stroke Prevention
  • Post-PCI Management
  • Blood Clot Prevention

Investigations into optimizing antithrombotic therapy and reducing cardiovascular complications.

03 Oncology Research

Advanced studies in breast cancer treatment, particularly focusing on hormone receptor-positive, HER2-negative variants. Research includes innovative approaches to disease management and treatment optimization.

  • Metastatic Breast Cancer
  • Rectal Cancer Treatment
  • Treatment Sequencing

Trials evaluate both pre-surgical and post-surgical treatment strategies for optimal patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.